In order to identify therapeutic targets and prognostic markers for basal breast cancers, breast cancer cell lines were subjected to mass spectrometry-based profiling of protein tyrosine phosphorylation events. This revealed that luminal and basal breast cancer cells exhibit distinct tyrosine phosphorylation signatures that depend on pathway activation as well as protein expression. Basal breast cancer cells are characterized by elevated tyrosine phosphorylation of Met, Lyn, EphA2, EGFR and FAK, and Src family kinase (SFK) substrates such as p130Cas. SFKs exert a prominent role in these cells, phosphorylating key regulators of adhesion and migration and promoting tyrosine phosphorylation of the receptor tyrosine kinases EGFR and Met. Consistent with these observations, SFK inhibition attenuated cellular proliferation, survival and motility. Basal breast cancer cell lines exhibited differential responsiveness to small molecule inhibitors of EGFR and Met that correlated with the degree of target phosphorylation, and reflecting kinase co-activation, inhibiting two types of activated network kinase (eg EGFR and SFKs) was more effective than single agent approaches. FAK signalling enhanced both proliferation and invasion, and Lyn was identified as a pro-invasive component of the network that in breast cancer patients is associated with a basal phenotype and poor prognosis. These studies highlight multiple kinases and substrates for further evaluation as therapeutic targets and biomarkers. However, they also indicate that patient stratification based on expression/activation of drug targets, coupled with use of multi-kinase inhibitors or combination therapies, may be required for effective treatment of this breast cancer subgroup.
Introduction
Gene expression profiling has revealed five breast cancer subtypes that differ in their prognosis and therapeutic responsiveness: luminal A and B (both estrogen receptor (ER)-positive), erbB2 (also known as HER2), basal and normal-like (ER-negative) (1) . Of these, the erbB2 and basal subsets exhibit the shortest overall and relapse-free survival. The basal subtype accounts for 10-27 % of breast cancer cases, depending on the patient population (2, 3) . The common absence of ER, progesterone receptor (PR) and erbB2 in this subgroup, or 'triple-negative' phenotype, leads to clinical resistance to endocrine and trastuzumab-based therapies (2) . In addition, basal breast cancers exhibit heterogeneity in terms of prognosis, but markers that accurately stratify patients at primary diagnosis are currently unavailable (2) . Consequently, critical issues facing the clinician are the lack of targeted treatment strategies and prognostic markers for this patient subset.
Approximately half of the tyrosine kinase complement of the human 'kinome' is implicated in human cancers (4) , and provides important targets for cancer treatment, as well as biomarkers for patient stratification. Characterization of tyrosine kinase signaling networks has been greatly facilitated by recent advances in mass spectrometry (MS)-based phosphoproteomics (5) . In the current manuscript we have utilized MS-based phosphoproteomic profiling to characterize the tyrosine kinase signaling networks associated with different breast cancer subgroups. This has revealed a tyrosine phosphorylation signature that characterizes the basal phenotype, and identified a prominent Src family kinase (SFK) signaling network in basal breast cancer cells. These findings provide important insights into the biology of basal breast cancers and have significant implications for development of therapeutic strategies that target this disease subtype.
Materials and Methods

Cell culture
All cell lines were obtained from the American Type Culture Collection, except for MDA-MB-231 and T-47D (EG and G Mason Research Institute) and MCF-7 (Michigan Cancer Foundation). Cell lines were authenticated by STR, SNP and fingerprint analyses, passaged for less than 6 months, and cultured as previously described (6, 7) .
Phosphoproteomic profiling
Phosphopeptide immunoprecipitation was performed as described (5) . Immunoprecipitated peptides were dissolved in 1 % (v/v) formic acid, 0.05 % (v/v) heptafluorobutyric acid. For each MS measurement, the samples were separated by nano-LC using an Ultimate 3000 HPLC and autosampler system (Dionex) and mass spectra were collected with an LTQ FT Ultra mass spectrometer (Thermo Electron). Peak lists were created from the raw data using the Mascot Distiller algorithm version 2.2.1.0 (Matrix Science). The Mascot Daemon tool version 2.2.0 (Matrix Science) was used to search the peak lists against an in-house sequence database extracted from ftp://ftp.expasy.org/databases/uniprot/knowledgebase (release date 19.12.2008) , with Homo sapiens set for taxonomy (20,411 sequences) . Final filtering criteria were applied to achieve a false positive rate for peptide identifications <1 %. Spectral counting was used to estimate the degree of phosphorylation for a particular protein or site. The average was calculated from replicates and data were normalised for the spectral counts of GSK3alpha/beta (5). Complete linkage hierarchical clustering and assembling of heat maps were carried out with an Euclidian distance matrix upon lntransformed data using TIGR's MeV program version 4.1 (8) . When comparing MCF-10A and MCF-10A/SrcY527F cells, phosphorylation sites exhibiting a difference in mean spectral counts of at least 1.5 in two independent experiments were considered as differentially phosphorylated.
Tyrosine kinase inhibitors
For phosphorylation assays, cells were treated with PP2 (Calbiochem) (30 μM) or Src kinase inhibitor I (Src-I1) (Calbiochem) (10 μM) for 1 h. For proliferation assays, PP2 was used at 10 μM.
AG1478 and SU11274 were obtained from Sigma and used at a final concentration of 10 μM and 1 μM, respectively. PF-562271 was obtained from Symansis and used at 1-100 nM. All drugs were dissolved in DMSO.
siRNA transfection
Lyn siRNAs "#12" and "#13" were obtained from Qiagen (Hs_LYN_12_HP and Hs_LYN_13_HP Validated siRNA). The sequence for Lyn siRNA "#2" was 5'-AAUGGUGGAAAGCAAAGUCCC-3', for FAK siRNA "#1" and "#2" 
Cellular assays
Proliferation was assayed using a MTS assay (Promega). Soft agar assays were as described previously (9) . For apoptosis assays, cells were drug-treated for 24 h and the sub-G 1 population was determined by flow cytometry. Significance was assessed by one-way ANOVA across treatments.
Cell tracking and determination of cell invasion through Matrigel (BD BioCoat Growth Factor
Reduced Matrigel Invasion Chamber, BD Biosciences) were undertaken as previously described (10, 11) .
Immunofluorescent staining of mouse mammary tumours tp53-null mammary tumors were generated by transplanting epithelium from tp53 null mice (Jackson Laboratory; FVB/N background; stock no.002899) into the cleared mammary fat pads of recipient wildtype FVB/N mice (12) . PyMT tumours were derived from MMTV-PyMT transgenic mice on an FVB/N background (13) . All animal work was approved by the Garvan/St Vincent's Hospital Animal Ethics Committee. Immunofluorescence analysis of frozen tumour sections was as previously described (14) .
Immunohistochemical staining of breast cancer specimens
The clinicopathological characteristics of the cohort and its subclassification are described elsewhere (15) . Ethics approval for the study was granted by the Human Research Ethics 
Reverse phase protein arrays (RPPAs)
The study population consisted of 107 patients with primary breast carcinomas treated in the Edinburgh Breast Unit (Table S1 ). The study was approved by the Lothian Research Ethics
Committee (08/S1101/41). Tumours were assessed for ER and PR positivity by IHC and HER2
positivity by IHC and FISH as previously described (16 
Results
Phosphotyrosine profiling of human breast cancer cell lines
The PhosphoScan approach (5) was applied to a panel of 15 breast cancer cell lines. We identified 544 sites of tyrosine phosphorylation in peptide sequences derived from 295 nonredundant proteins (Tables S2 and S3 ). Thirty-one tyrosine phosphorylation sites were previously unidentified (Table S4 ).
Upon unsupervised hierarchical clustering using data for all tyrosine-phosphorylated proteins, the cell lines largely clustered into two groups previously characterized as 'basal' or 'luminal' by transcript profiling (11) ( Figure 1A ). Co-clustering of lines classified as basal A and basal B (stem cell-like), respectively, was also evident (11) . A distinct erbB2 subgroup was not resolved, as observed in transcript profiling studies (11, 18) . In addition, proteins and individual phosphorylation sites were ranked according to the difference in median phosphorylation between the basal and luminal groups (Figure 2A and B).
Clustering of cell lines using these top-ranked proteins or sites led to resolution of basal and luminal clusters that was not evident when the process was undertaken using randomly-selected proteins or sites, validating the ranking process ( Figure 2 and data not shown). Increased phosphorylation of several tyrosine kinases (Met, Lyn/Hck, EphA2, EGFR, and FAK) was characteristic of basal lines.
In addition, we detected enhanced phosphorylation of the predicted pseudokinase SgK269, and Phosphorylation on these sites was not significantly different between HER2 cancers and the other phenotypes.
We characterized the expression of Lyn over a large breast cancer patient cohort (15) . High Lyn expression (> mean H score) was strongly associated with the basal subtype (p<0.0001 by χ 2 analysis), but not the other subtypes, including HER2 ( Figure 3C ). High Lyn expression was associated with reduced survival (p=0.04, HR = 1.88, Figure 3D ), but it was not an independent prognostic marker in multivariate analysis with the final resolved model incorporating PR expression, HER2 amplification and lymph node status. These data confirm that our profiling Figure 4C ). Overall, these data indicate that SFK activity is a major contributor to the tyrosine phosphorylation signature characteristic of basal breast cancer cells ( Figure 5 ).
Sensitivity of basal breast cancer cell lines to EGFR, Met and SFK tyrosine kinase inhibitors (TKIs)
The identification of a prominent SFK signaling network led us to determine the biological effects of inhibiting SFK activity. Also, since basal breast cancer cells exhibit increased activation of EGFR and Met, we tested the efficacy of TKIs directed against these kinases. However, since the degree of activation of these RTKs in basal breast cancer cell lines varies (Figure 2 ), we tested whether the sensitivity of the cell lines to corresponding TKIs depends upon the target activation profile. In addition, co-activation of several tyrosine kinases in basal breast cancer cells may promote resistance to individual TKIs. Therefore, we determined whether particular combinations of inhibitors were more effective than single agents.
Three cell lines were chosen for this analysis: HCC1954 exhibits high phosphorylation of both the EGFR and Met; BT20, the EGFR; and BT549, Met. All three lines exhibit a phosphorylation signature characteristic of SFK signaling (Figure 2) . Proliferation of the HCC1954 and BT20 cell lines, but not BT549 cells, was significantly inhibited by the EGFR inhibitor AG1478 ( Figure 6A ). When used alone, the Met inhibitor SU11274 was without effect on any line ( Figure 6A and data not shown). The SFK inhibitor PP2 inhibited proliferation of HCC1954 and BT20 cells ( Figure 6A ), and markedly increased apoptosis in the former cell line ( Figure 6B ). Next, we tested combinations of TKIs. Co-administration of SU11274 and AG1478 to HCC1954 cells led to further growth inhibition compared with AG1478 alone. This effect was not evident in the other cell lines that do not exhibit high activation of both EGFR and Met ( Figure 6A and data not shown).
Combining PP2 and SU11274 did not result in enhanced inhibition compared to PP2 alone for any cell line (data not shown). However, co-administration of PP2 and AG1478 to HCC1954 and BT20 cells led to further inhibition of proliferation compared with single agent treatments ( Figure 6A ).
Importantly, combining these drugs also led to increased cell death, particularly in BT20 cells ( Figure 6B ). Throughout these experiments we noted that inhibitory effects of particular TKIs on Consequently, while some basal breast cancers may be refractory to growth inhibition by SFK inhibitors, these agents may still be of clinical benefit by attenuating processes linked to metastatic spread.
Overall, these data indicate that responses to TKIs in basal breast cancer cells are not uniform but are dependent on kinase activation profiles, and that combination-based approaches may be most effective. Specifically, they demonstrate that the EGFR and SFKs represent attractive therapeutic targets, particularly in combination.
Characterization of the biological roles of FAK and Lyn in basal breast cancer cells
Two additional candidates identified by our profiling were subject to functional analysis:
FAK, as it represents a key 'node' of the basal breast cancer signalling network ( Figure 5) ; and Lyn, as we had confirmed the association of this SFK with basal breast cancer using our patient cohort Figure 7A ). In addition, we determined the effects of reducing FAK protein expression via siRNAmediated knockdown ( Figure S3B ). This led to a significant reduction in anchorage-dependent cell proliferation, as well as a marked reduction in cell invasion ( Figure 7B ). These data indicate that under anchorage-dependent conditions, basal breast cancer cells are more sensitive to attenuation of
Discussion
In this study we have used a global phosphoproteomic approach to characterize phosphotyrosine-based signaling networks in breast cancer cells of contrasting phenotypes, providing a rich information resource that complements those describing genomic and transcriptomic alterations (11, 31) . This approach has identified that SFKs govern a signaling network in basal breast cancer cells that extends not only downstream to canonical SFK substrates regulating cell adhesion and migration but also upstream to specific RTKs, and that Lyn is a key 
